Welcome to our dedicated page for Korro Bio news (Ticker: KRRO), a resource for investors and traders seeking the latest updates and insights on Korro Bio stock.
Korro Bio, Inc. (KRRO) is a biopharmaceutical innovator developing RNA-based genetic therapies for both rare and common diseases. This news hub provides investors and industry observers with essential updates on the company's scientific advancements and strategic developments.
Access curated press releases and objective analysis covering clinical trial progress, research collaborations, and regulatory milestones. Our collection focuses on KRRO's unique RNA editing platform that enables precise, transient genetic modifications - a differentiated approach in therapeutic development.
Key updates include therapeutic pipeline advancements, partnership announcements with academic institutions, and financial disclosures. Bookmark this page for centralized access to KRRO's latest developments in oligonucleotide-based treatments and their potential impact on genetic medicine.
Korro Bio presented new preclinical data on KRRO-110 at the 2024 American Thoracic Society International Conference. The data demonstrated sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to over 60µM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) mouse model. Notably, KRRO-110 showed 35µM of M-AAT one week post the first dose, rising to 45µM of M-AAT by week 13. This data suggests KRRO-110's potential as a best-in-class therapeutic for AATD. Korro plans to submit a regulatory filing for a first-in-human study in the second half of 2024.
Korro Bio (Nasdaq: KRRO) reported its financial results for Q1 2024 and announced the appointment of Dr. Kemi Olugemo as Chief Medical Officer. Significant milestones include a $70 million private placement completed in April 2024, increasing cash reserves to $206 million. This funding extends Korro's cash runway into the second half of 2026. Pipeline progress includes plans for a regulatory filing for KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD), in the latter half of 2024. Interim readout for KRRO-110 is expected in H2 2025, with trial completion in 2026. Financial highlights show a decrease in cash from $166.1 million to $138.8 million and a net loss of $19.6 million for Q1 2024, unchanged from the previous year. R&D expenses dropped to $13.6 million, while G&A expenses rose to $7.9 million.
FAQ
What is the current stock price of Korro Bio (KRRO)?
What is the market cap of Korro Bio (KRRO)?
